Agios said it is ending development of tebapivat in low-risk myelodysplastic syndromes after Phase 2b results fell short. The pyruvate kinase activator, designed to improve cellular energy metabolism in certain blood cancers, had been pursued for a subset of MDS patients, but the latest data reduced confidence in continued investment. For investors and competing developers of metabolic and hematology agents, the decision highlights the high bar for Phase 2b readouts in rare-blood settings and the need for clear differentiators—whether based on response depth, durability, or biomarker stratification. Agios’s move also clears internal capital toward other pipeline priorities, while reminding the market that targeted metabolic strategies can still miss on efficacy in broader MDS populations.